Back

Guideline recommended therapies and clinical outcomes according to the risk for recurrent cardiovascular events after an acute coronary syndrome

27 August 2018 (15:16 - 15:26)
Organised by:
Congress Presentation Part of: Beta blockers: required in all acute coronary syndromes? Treatment ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Yoav Hammer

Rabin Medical Centre, Petah Tikva (Israel)

5 More presentations in this session

Presentation thumbnail
Should we use beta-blockers in all patients after st-segment elevation acute myocardial infarction?
Doctor J. Ferreira (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Beta-blockers and cardiovascular outcomes in patients hospitalized for acute coronary syndrome without heart failure
Slides Video
Presentation thumbnail
Effects of selective and nonselective beta-blockers on platelet aggregation in patients with acute coronary syndrome: the PLATE-BLOCK study
Doctor F. Ilardi (Napoly, IT)
Abstract Slides Video
Presentation thumbnail
The effect of optimal medical therapy on hospital discharge on 3-year mortality after acute myocardial infarction in patients undergoing primary percutaneous intervention
Assistant Professor Z. Mehmedbegovic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
One year survival benefit of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in acute coronary syndrome undergoing PCI according to left ventricular ejection fraction.
Doctor M. Cespon Fernandez (Vigo, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Beta blockers: required in all acute coronary syndromes?

The Event

Event poster

ESC Congress 2018

27 August 2018 15:16 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources